Navigation Links
Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Date:8/23/2007

enable differentiated therapeutics with its industry-leading pulmonary and PEGylation technology platforms. Nektar pulmonary and PEGylation technology, expertise, manufacturing capabilities and know-how have enabled nine approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its pulmonary and PEGylation technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements that reflect the company's current views as to its management team, revenue potential, product pipeline potential and business prospects. These forward- looking statements involve risks and uncertainties, including but not limited to: (i) the company's proprietary product candidates and those of certain of its partners are in the early phases of clinical development and the risk of failure is high and can occur at any stage prior to regulatory approval, (ii) the company's or its partner's ability to obtain regulatory approval for product candidates, (iii) the success of the company's partners in sales and marketing efforts to generate from approved products and future products (if any), and (iv) the company's patent applications for its technology platforms and proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or intellectual property licenses from third parties may be required in the future. Important risks and uncertainties are detailed in the company's reports and other filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of n
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Sharon Ethanol appoints operations director
3. Kyron appoints former AMA chairman to board
4. Brady appoints GE efficiency expert as CTO
5. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
6. Johnson Controls appoints Roell to head EOC
7. SecurePipe appoints two senior execs
8. Milwaukees PointOne appoints new president and CEO
9. Third Wave appoints new chairman
10. Midwest Venture Summit disappoints; Cato grades Midwest governors
11. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Biotechnology industry pioneer Amgen (NASDAQ: ... BlackLine Systems  and enterprise application software leader ... webinar next week entitled "No Account Left Behind!  ... to Help Keep Its Account Reconciliations in Good Shape ... The webinar, geared at finance, accounting, audit and compliance ...
(Date:6/19/2013)... BioConvergence team members Curtis Strother ... 2013’s BioLogistics Summit in San Francisco earlier this ... Chain IQ and IQPC, addressed the increasingly complex ... part, attributed to current trends of globalization, outsourcing, ... trends is an increase in movement, which is ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased ... measurement of sulfur in ultra-low sulfur diesel (ULSD) using ... EDXRF analyzer . The analysis detailed in Rigaku Application ... This International Standard specifies an energy dispersive X-ray ... content in automotive gasoline. , Regulations around the world ...
(Date:6/19/2013)... 19, 2013 Express Diagnostics Int’l, Inc., ... announced that it has received Class III medical device ... its DrugCheck® NxStep Onsite Drug Screen Cup ... rapid screening device in near-patient settings, such as physicians’ ... received Health Canada Class III approval for 24 different ...
Breaking Biology Technology:Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 2Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 4BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
... Encorium Group, Inc. (Nasdaq: ENCO ), a full service ... for many of the world,s leading pharmaceutical and biotechnology companies, today ... Nasdaq stating that since it had not, as of the date ... June 30, 2009, it was then no longer in compliance with ...
... , MURRIETA, Calif., Aug. 27 Despite ... of its US operations. Copan Diagnostics, Inc. is undertaking a ... and additional medical device manufacturing operations to its facility in ... molding machinery and filling and packing equipment to expand Copan,s ...
... , , , , ... PPHM ) today announced that it will release its financial results for ... 7:00 a.m. EDT and will host a conference call and webcast to ... , Peregrine,s senior management will discuss financial results for ...
Cached Biology Technology:Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing 2Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing 3Copan Announces Multimillion Expansion for US Pipet Manufacturing Operations 2Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results 2
(Date:6/19/2013)... June 19, 2013 MedNet Solutions , ... study management systems, is pleased to announce its participation ... June 23-27 in Boston .  This ... recognized leader in cloud-based eClinical solutions, has exhibited at ... showcasing iMedNet™ EDC , MedNet,s latest, ...
(Date:6/19/2013)... the most perfectly spherical large objects in nature may ... new study. It appears in ACS, journal Langmuir ... Julyan Cartwright, Antonio G. Checa and Marthe Rousseau point ... have perhaps the most perfectly spherical, or ball-like, shape ... without a microscope. Pearls develop as nacre (mother of ...
(Date:6/19/2013)... 2012, the European Medicines Agency (EMA) approved the ... ever gene therapy for clinical use in the ... developed AAV-LPL S447X for the treatment of a ... (LPLD) which affects approximately one or two out ... life-threatening inflammations of the pancreas. Afflicted individuals carry ...
Breaking Biology News(10 mins):MedNet Solutions To Spotlight iMedNet EDC At The 49th DIA Annual Meeting 2No danger of cancer through gene therapy virus 2
... Cones, holes and temporary traffic lights the scourge of ... together to reduce the misery of motorists caused by ... under the tarmac. They,ll reveal how new technology will ... digging. A sector-wide seminar at The University of ...
... New Orleans, LA Research led by David Worthylake, PhD, ... Sciences Center New Orleans, may help lay the groundwork for ... cancer. The research will be published in the May 29, ... During the transition from a localized tumor to metastatic ...
... NOT trying to assert their dominance over their canine ... at the University of Bristol,s Department of Clinical Veterinary ... Applications and Research . The researchers spent six ... rehoming centre, and reanalysing data from studies of feral ...
Cached Biology News:Reducing the roadworks 2Reducing the roadworks 3LSUHSC research describes function of key protein in cancer spread 2Using 'dominance' to explain dog behavior is old hat 2
... BAS-2500 is ideal for ... Biology (1D electrophoresis, 2D ... Macroarrays); Pharmacokinetics & Toxicology ... layer chromatography); Physical and ...
BlotGel application pool -see Blotters (Semi-Dry) for more info...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human HLA-DR TAC is designed to deplete human HLA-DR from samples to isolate resting CD4+ or CD8+ T cells....
When added to StemSep T Cell Enrichment cocktail, human TCRab TAC is designed to deplete human TCRab from samples to isolate gd T cells....
Biology Products: